scholarly journals Активність матриксних металопротеїназ ММП2 та ММП9 у пацієнтів з мієло- та лімфопроліферативними захворюваннями

2014 ◽  
Vol 5 (1) ◽  
pp. 54-57
Author(s):  
I. A. Gordiienko
Keyword(s):  
Multiple Myeloma ◽  
Acute Myeloid Leukemia ◽  
Chronic Lymphocytic Leukemia ◽  
Myeloid Leukemia ◽  
Basement Membranes ◽  
Lymphocytic Leukemia ◽  
Chemotherapeutic Drugs ◽  
Malignant Cells ◽  
Anthracycline Antibiotics ◽  
Acute Myeloid

MMP2 and MMP9 matrix metalloproteinases due to their ability to destroy basement membranes collagen and remodeling extracellular matrix (ECM) in the micro-environment of blood progenitor cells in the bone marrow play the important role in hematopoiesis. Displacement of normal hematopoiesis and dissemination of malignant cells in proliferative diseases of blood is also accompanied by catalytic ECM rearrangement. However, it is not known exactly how activity of MMP2 and MMP9 changes in various forms of leukemia and how it is affected by chemotherapeutic drugs. The aim of this study was to determine the influence of anthracycline antibiotics (daunorubicin and adriablastin) on MMP2 and MMP9 activity in blood plasma of patients with acute myeloid leukemia, chronic lymphocytic leukemia and multiple myeloma. It was established that proMMP9 activity was significantly reduced (0,03 ± 0,01 rel. u.) in patients with acute myeloid leukemia before the treatment, however, after chemotherapy, it increased approximately 7 times. Chronic lymphocytic leukemia and multiple myeloma were accompanied by significant increase of MMP9 activity. Application of daunorubicin led to decrease of proMMP9 activity (0,25 ± 0,10 rel. u.) in patients with chronic lymphocytic leukemia. ProMMP9 activity was significantly reduced (16 times) and that of MMP9 increased in case of multiple myeloma. In studying of MMP2 activity it did not significantly change. The conclusion is that the ratio of proMMP9/MMP9 can be used as the additional criterion for monitoring the effectiveness of chemotherapy of proliferative diseases of blood. 

scholarly journals A Case of Acute Myeloid Leukemia Concurrent With Untreated Chronic Lymphocytic Leukemia

2017 ◽  
Vol 37 (4) ◽  
pp. 336-338
Author(s):  
Hye-Young Lee ◽  
Chan-Jeoung Park ◽  
Enkyung You ◽  
Young-Uk Cho ◽  
Seongsoo Jang ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Chronic Lymphocytic Leukemia ◽  
Myeloid Leukemia ◽  
Lymphocytic Leukemia ◽  
Acute Myeloid

Soluble CD44 Is Increased in Haematopoietic Stem Cell Grafts of Patients with Acute Myeloid Leukemia, Multiple Myeloma and Non-Hodgkin’s Lymphoma.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3286-3286
Author(s):  
Daniela S. Krause ◽  
Christopher P. Stowell
Keyword(s):  
Multiple Myeloma ◽  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Clinical Outcome ◽  
Myeloid Leukemia ◽  
Haematopoietic Stem Cell ◽  
Malignant Cells ◽  
Haematological Malignancies ◽  
Soluble Cd44 ◽  
Acute Myeloid

Abstract Autologous haematopoietic stem cell transplantation (autoHSCT) after high dose chemotherapy is a widely used form of therapy for patients with leukemia, lymphoma and multiple myeloma. Malignant cells remaining in the graft, however, may reengraft leading to relapse of the original disease. CD44, a transmembrane glycoprotein, which is overexpressed in many malignancies, including most haematological malignancies, and which plays a role in the engraftment of leukemia-initiating cells, is shed from the surface of malignant cells. In order to establish whether there is a correlation between the amount of CD44 shed from the surface of the malignant cells with the number of contaminating cells remaining in the graft, the engraftment potential of the malignant cell population, or clinical outcome after autoHSCT, we measured soluble CD44 (sCD44) in 86 haematopoietic stem cell grafts from patients with haematological malignancies by enzyme-linked immunosorbent assay (ELISA) and compared the results to sCD44 levels in the HSC grafts from 33 healthy donours. The levels of sCD44 were almost 2fold higher in the grafts of patients with acute myeloid leukemia (AML) (mean: 30,015 ng/ml ± 8524), multiple myeloma (mean: 27,564 ng/ml ± 7,801) and diffuse large B-cell Non-Hodgkin-Lymphomas (mean: 22,539 ng/ml ± 8,382) than in healthy HSC donour grafts (mean: 13,035 ng/ml ± 10,075). As expected, levels of sCD44 were highest in auto HSCT grafts of patients with AML. The majority of patients who achieved a complete remission after autoHSCT had relatively low sCD44 values (mean: 22,610 ng/l ± 7439). Levels of sCD44 were greatest in patients who experienced progressive disease (mean: 28,918 ng/ml ± 10,431), and somewhat less elevated in patients with relapsed disease after auto HSCT (mean: 26,171 ng/ml ± 7616). In addition, patients who had levels of sCD44 <25,500 ng/ml had increased survival (33% at 120 months after autoHSCT versus 18% in patients with sCD44 levels of >25,500 ng/ml). These results argue that the levels of soluble CD44 in an HSC graft could serve as a biomarker for the engraftment potential of contaminating malignant cells in the graft, and may correlate with clinical outcome after autoHSCT. Further, these results raise the possibility that CD44 blocking strategies may be beneficial in autoHSCT.

Sign in / Sign up

Export Citation Format

Share Document